Meta-analysis could not be performed because of lack of sufficient comparable data.
Numbers needed to treat (NNT) for the analgesic effect could also not be produced. Instead …

BA CKGROUND: Transdermal therapeutic systems offer potential advantages over oral or
intravenous routes of drug administration. The purpose of this prospective study was to …

We performed an open-label pilot study to define analgesic efficacy, acceptability, and
toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our …

Objective: The aim of this study was to assess the effectiveness and safety of transdermal
fentanyl for the treatment of moderate or severe cancer-related pain. Materials and Methods …

A multicenter study was conducted to determine the patient and physician acceptability of
transdermal fentanyl in the management of cancer-related pain. In this study, 10 cancer …

8234 Background: Cancer patients with moderate-severe pain often require opioid
analgesics. Methods: From October 2002 to November 2003, 62 outpatients underwent …

The development of the passive transdermal therapeutic system (TTS) as an effective
method of drug delivery has allowed the potent, lipid soluble opioid fentanyl to be …

Many cancer patients are undermedicated and inappropriately managed for pain, leading to
a diminished quality of life. Patients with moderate to severe pain often require opioid …

Patients were entered into an open label study to evaluate the efficacy of transdermal
fentanyl as an analgesic for chronic cancer pain. The clinical course of 3 patients is …

Over the last 20 years, orally administered opioids have become the standard
pharmacological treatment for moderate to severe cancer pain (1). In most patients, pain can …